Copyright(c) 2011 Samsung Biomedical Research Institute All Rights Reserved.
- - George F. Vande Woude, PhD
- - Walter Birchmeier, PhD
- - Ermanno Gherardi, PhD
- - Gabriele Bergers, PhD
- - Do-Hyun Nam, MD, PhD
- - Sun Young Rha, MD, PhD
- - Yao Yao, PhD
- - Paolo M. Comoglio, MD, PhD
- - Young Suk Park, MD, PhD
- - John J. Laterra, MD, PhD
- - James G. Christensen, PhD
- - Teresa Burgess, PhD
- - Ling Liu, PhD
- - Soonmyung Paik, MD, PhD
- - Yoon-La Choi, MD, PhD
- - Kyeung Min Joo, MD, PhD
- - Paul Ho Yeong Song, PhD
[ Day I ] Oct. 7 (Friday)
| 08:30 ~ 09:00 | Registration | |
| 09:00 ~ 09:05 | Opening Remark | Joobae Park, MD, PhD |
| 09:05 ~ 09:10 | Welcome Address | Jongchul Rhee, MD, PhD |
| Overview 1 | Chair: Joobae Park | |
|---|---|---|
| 09:10 ~ 10:00 | Targeting c-Met in Human Cancer | George F. Vande Woude, PhD |
| 10:00 ~ 10:10 | Coffee Break | |
| Session I | Functional and Structural Biology of c-Met | Chair: Sunghoon Kim, Gou Young Koh |
| 10:10 ~ 10:50 | Wnt and Met Signaling in Stem and Cancer Stem Cells | Walter Birchmeier, PhD |
| 10:50 ~ 11:30 | Structure/Function of HGF/SF and MET | Ermanno Gherardi, PhD |
| 11:30 ~ 11:50 | Coffee Break | |
| 11:50 ~ 12:30 | Mechanisms of evasive resistance to VEGF inhibition in mouse models of glioblastoma | Gabriele Bergers, PhD |
| 12:30 ~ 13:00 | c-Met Signaling and Glioma Cancer Stem Cell Phenotypes | Do-Hyun Nam, MD, PhD |
| 13:00 ~ 14:30 | Lunch | |
| Session II | Clinical Significance of c-Met | Chair: Jungshin Lee |
| 14:30 ~ 15:10 | c-Met as a Therapeutic Target in Gastric Cancer | Sun Young Rha, MD, PhD |
| 15:10 ~ 15:50 | Translational Research on INC280, A Selective Small Molecule inhibitor of c-Met | Yao Yao, PhD |
| 15:50 ~ 16:20 | The MET Oncogene: from molecular biology to the clinic | Paolo M. Comoglio, MD, PhD |
| 16:20 ~ 16:40 | Coffee Break | |
| 16:40 ~ 16:55 | Role of Clinical Trial Center for Future Medicine | Young Suk Park, MD, PhD |
| 16:55 ~ 17:05 | Introduction of Institute for Refractory Cancer Research in Samsung Medical Center | Do-Hyun Nam, MD, PhD |
| 17:05 ~ 17:10 | Closing |
[ Day Ⅱ ] Oct. 8 (Saturday)
| Overview 2 | Chair: Keunchil Park | |
|---|---|---|
| 08:30 ~ 09:10 | c-Met and Tumor Cell Reprogramming | John J. Laterra, MD, PhD |
| Session III | Targeting c-Met: Small Molecules & Antibodies | Chair: In-Chull Kim |
| 09:10 ~ 09:50 | The Development of Crizotinib for Molecularly Targeted Patient Populations | James G. Christensen, PhD |
| 09:50 ~ 10:30 | Targeting HGF/c-Met Signaling with Rilotumumab (AMG 102), a Fully Human Monoclonal Antibody Against HGF: From Discovery Research to Phase 2 Clinical Activity | Teresa Burgess, PhD |
| 10:30 ~ 11:00 | LA480, a c-Met Antibody with Neutralization and Internalization Properties, Inhibits HGF-dependent and HGF-independent c-Met Pathway Activation and Tumor Growth | Ling Liu, PhD |
| 11:10 ~ 11:30 | Coffee Break | |
| Session Ⅳ | Targeting c-Met: Companion Diagnostics | Chair: Keunchil Park |
| 11:30 ~ 12:00 | Prediction of Benefit from Targeted Therapies for Breast Cancer | Soonmyung Paik, MD, PhD |
| 12:00 ~ 12:20 | Companion Diagnosis for MET: Guiding Therapy Decisions | Yoon-La Choi, MD, PhD |
| 12:20 ~ 12:40 | Avatar Mice: Glioblastoma Animal Models Closely Mirror Individual Tumors | Kyeung Min Joo, MD, PhD |
| 12:40 ~ 13:00 | Generation and functional characterization of a novel c-Met antibody | Paul Ho Yeong Song, PhD |
| 13:00 ~ 14:30 | Lunch | |
| Panel Discussion | Future Directions for c-Met in the Drug Development | Chair: Paolo M. Comoglio |
| 14:30 ~ 15:00 | Symposium Highlights | Paolo M. Comoglio, MD |
| 15:00 ~ 16:45 | Discussion Agenda - Next c-Met International Symposium - Establishing International c-Met Society |
|
| 16:45 ~ 16:50 | Closing Remark | Do-Hyun Nam, MD, PhD Chairman, SISMM |
| 17:00 ~ 19:00 | Discussion |